Amicus Getting Ready to Submit NDA for Migalastat to Treat Fabry
BET Inhibitor Being Developed to Treat Fabry Disease
Fixing the Genetic Information on the Internet
NORD's Rare Impact Award Winners Announced
ThinkGenetic - Data Collecting
Phase 3 Trial of Agalsidase Beta in Pediatric Patients with Fabry Disease
Gene Therapy for Fabry Disease Now a Reality
Can Depression in Fabry Patients be Managed via Teleconference?
FDA Requests Additional Data for Amicus' Fabry Disease Treatment
Pivotal Migalastat - Fabry Study Published in NEJM
Positive Results in Plant-based ERT Study Treating Fabry Patients
Fabry Drug Approved in Europe. U.S. Approval Unknown.
Next Page >>
MOST POPULAR ARTICLES
Q&A with Hartmann Wellhoefer, Shire's VP and Head of Medical Affairs; Rare Diseases & Internal Medicine
Neuroblastoma Treatment Granted Orphan Drug Designation
Galinpepimut-S Safe and Effective in Multiple Myeloma
Nintedanib Gets Fast Track Designation for Treatment of Systemic Sclerosis
STRATEGIC ALLIANCE PARTNERSHIP PROGRAM >
Familial Chylomicronemia Syndrome
MJH ASSOCIATES >
Specialty Pharmacy Times
Terms & Conditions
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.